SavedAdd your journal

Journals / Annals of Medical Research / 2021 / Cilt: 28 - Sayı: 7

Efficacy and Safety of flecainide p.os. in cardioversion ofrecent-onset atrial fibrillation

Ioannis VOGIATZIS
Evangelos SDOGKOS
Konstantinos KOUTSAMPASOPOULOS
Savas GRIGORIADIS
Sarantis PITTA
Pages
1400–1405
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Aim: The aim of the study was to identify the level of safety and the efficacy of flecainide per o.s. in patients with recent-onset (

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of the study was to identify the level of safety and the efficacy of flecainide per o.s. in patients with recent-onset (
📊
Key Findings & Data:Aim: The aim of the study was to identify the level of safety and the efficacy of flecainide per o.s. in patients with recent-onset (
💡
Conclusion & Impact:Aim: The aim of the study was to identify the level of safety and the efficacy of flecainide per o.s. in patients with recent-onset (
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: The aim of the study was to identify the level of safety and the efficacy of flecainide per o.s. in patients with recent-onset (

🔖

Cite This Article

VOGIATZIS, I., SDOGKOS, E., KOUTSAMPASOPOULOS, K., GRIGORIADIS, S., PITTA, S. (2022). Efficacy and Safety of flecainide p.os. in cardioversion ofrecent-onset atrial fibrillation. Annals of Medical Research, Cilt: 28 - Sayı: 7, 1400–1405. https://ajindex.com/articles/446277

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Miyasaka Y, Barnes M, Gersh B, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25
  2. Alan G, Hylek E, Phillips K, et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
  3. Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol 2007;18:628-33
  4. Alboni P, Botto GL, Baldi N, Luzi M, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004;351: 2384-91
  5. Mairesse M, Moran P, Gelder I, et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Europace 2017;19:1589-623
  6. Luchsinger JA, Steinberg JS. Resolution of cardiomyopathy after ablation of atrial flutter. J Am Coll Cardiol 1998;32:205-10
  7. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92:1954-68
  8. Andrade JG, Macle L, Nattel S, et al. Contemporary Atrial Fibrillation Management: A Comparison of the Current AHA/ACC/HRS, CCS, and ESC Guidelines. Can J Cardiol 2017;33:965-76
  9. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001;37:542-7
  10. Reisinger J, Gatterer E, Heinze G, et al. Prospective comparison of flecainide vs sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998;81:1450-4
  11. Lloyd-Jones D, Wang T, Leip E, et al. Lifetime risk for development of atrial fibrillation. The Framingham Heart Study. Circulation 2004;110:1042-6
  12. Hisashi O, Yoshimori A, Syuhei I, et al. Progression from paroxysmal to sustained atrial fibrillation is associated with increased adverse events. Stroke 2018;49:2301-8
  13. Andersen S, Hansen M, Gislason G, et al. Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide st